bioMérieux Announces CLARION™ Infectious Diseases and Diagnostics Software

19 November, 2020

The innovative software-as-a-service reflects growing capabilities and global mission for antimicrobial stewardship and surveillance.

Durham, NC (Nov. 19, 2020) – bioMérieux, a world leader in in vitro diagnostic solutions for infectious disease, is pleased to announce CLARION™, its pioneering clinical informatics software that connects diagnostic data in the United States of America. The announcement coincides with World Antimicrobial Awareness Week and reflects bioMérieux’s goal to provide multiple solutions to combat antibiotic overuse and inappropriate use worldwide.

CLARION™, the infectious disease diagnostics software-as-a-service (SaaS) solution, is designed for labs and hospitals to provide critical infectious disease data and insights to support antimicrobial stewardship programs (ASP). It also provides much needed visibility to the value of diagnostics, such as Procalcitonin (PCT) testing, generated for healthcare systems.

The World Health Organization reports that worldwide escalation in antibiotic resistance has sparked fear of a looming post-antibiotic era. Antibiotic overuse and inappropriate use – including over-prescribing, inaccurate, and suboptimal prescribing –promotes bacteria to evolve and become resistant to treatment, currently leading to 35,000 deaths annually in the U.S. and 700,000 deaths annually worldwide. By 2050, conservative estimates predict 10 million deaths per year globally, with cumulative economic costs of at least $100 trillion if actions are not taken now to curtail antimicrobial resistance. Antibiotic resistance is a crisis that cannot be tackled without tailored ASP technologies built for the task.

“When lives are at stake, access to data and speed to insight are critical,” said Dr. John Hurst, Sr. Dir of Antimicrobial Stewardship for Enterprise Business Management at bioMérieux USA. “Our cloud technology is delivering results in seconds that previously took months to produce.”

CLARION™ supports laboratories and hospitals in the United States in fighting public health threats and is built for the battle against antimicrobial resistance (AMR). The software is intended for infectious diseases-related data and produces actionable insights through analytics and dashboards that support programs and government goals to curb inappropriate antibiotic use. It also equips those who oversee antibiotic use and monitor resistance to have the right data to collaborate with clinicians and create ‘handshake stewardship’ to help save lives. CLARION™ is part of bioMérieux’s comprehensive IT suite of products that address the various needs and challenges of our customers to fight AMR globally.

In pilot testing of the advanced analytic software with bioMérieux partner hospitals, the advantages experienced were significant, including saving clinical laboratories months of work to replicate what was previously time-consuming data preparation and analysis. Dr. Mike Broyles, leader of The Antimicrobial Stewardship Team at St. Bernard’s Five Rivers Medical Center said, “CLARION™ takes us far beyond the very shallow queries of the past and extends our ability to make more intelligent evaluations of the data, implement better strategies, and objectively assess outcomes from strategy changes.”

Data collection from the diverse and siloed hospital systems has been a primary challenge when identifying outcomes from biomarker utilization, such as PCT, and quantifying how diagnostic stewardship can drive value-based healthcare. CLARION™ allows for up-to-the-minute reports on use of PCT results according to hospital protocols, prescriber level protocol adherence and associated patient and operational outcomes. Dr. Broyles, who leverages PCT as part of the St. Bernard’s Five Rivers ASP said, “With CLARION™, we finally get access to valuable insights that have been previously locked away in laboratory, pharmacy and EMR systems.”

To learn more, visit

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for more than 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2019, revenues reached €2.7 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP


bioMérieux Media Relations contact:
Liza Deckelbaum

Download the Full Press Release:

Pioneering Diagnostics